Similar to other studies, our results demonstrated that ER−/PR+ BC had more unfavorable clinical features and more aggressive biological characteristics, such as a higher stage, a higher tumor grade, a higher proportion of CK5/6-positive status [4], higher HER2 expression [26], and higher Ki67 expression [24, 27], than ER+ BC. The gene discussed is MKI67; the disease is breast cancer.